ALK will also pay up to $320m in milestone payments to ARS in the deal, which sees the latter keep rights in the US, ...

DelveInsight’s “Post Bariatric Hypoglycemia Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an ...

Schizophrenia significantly shortens life expectancy by an estimated 15 years with excess mortality arising from multiple ...

Heritage is ponying up $10 million while Apotex is set to pay $39.1 million over the companies’ alleged roles in a sweeping ...

In 2020 it won a ruling that Teva’s product patent was invalid, and it was thus revoked across Europe. At the time, Synthon ...

11 October 2022 European Commission says pharma firm blocked generics over blockbuster MS drug| Teva “engaged in abusive conduct” to “artificially prolong the exclusivity” of Copaxone | Teva could be ...

The global glucosamine supplement market is projected to grow from USD 583.6 million in 2023 to USD 932.7 million by 2033, expanding at a CAGR of 4.8%, according to Future Market Insights. The rising ...

Global Dyspnea Treatment MarketThe global dyspnea treatment market, valued at USD 5.90 billion in 2022, is expected to experience robust growth, projected to reach approximately USD 12.3 billion by ...

If timing is everything, then Teva, the world's biggest maker of generic drugs, has chosen a tricky moment to try to pull off the biggest pharmaceuticals deal of the year. The Israeli group's proposed ...

Teva gets a buy rating as it trades well below 10-year highs and shows growth potential as the leading global generic drugmaker. Their drug pipeline is robust and diverse, as well as existing ...